Semis At An Inflection Point… And Navigating An ‘Expensive’ Market 9/18/26

18 Sep 2026 · 43 min · 24 chapters

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Fast Money episode focuses on a potential inflection point for semiconductors amid an “expensive” market. Guests debate whether semis will break higher after a chart “wedge,” arguing AI capex (about $1.3T next year for hyperscalers) remains intact despite negative sentiment and rate/oil risks. They cite converging trend lines and discuss SMH vs SOX positioning, with memory/margin pressure but NVIDIA’s larger weight. They also cover healthcare strength: biotech/device makers (Revity, Moderna, Dexcom, Thermo Fisher) outperforming despite higher-rate fears; AI is improving efficiency and shortening pipelines.

Guest

Carter Braxton Wirth (chart note author, referenced).

Guest

Jared Holt (Mizuho Healthcare Specialist) on Novo Investor Day (Novo’s rebrand/culture shift; pipeline beyond Wegovy; obesity “race” viewed as lost to Lilly; pricing dynamics and GLP-1 consumerization). Later: Mackenzie Cigales (iPhone 18 Pro demand/lead times/valuation) and Katerina Simonetti (Morgan Stanley) on diversification, avoiding mega-cap chasing, and using short-term bonds/cash.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Chapters

Tap a time to open that second in VO

Potential Inflection Point for Semis

0:32 to 0:52

Discussion on the current state of semiconductor stocks and market trends.

“Mazda has been named Consumer Reports' safest new car brand.”

Potential Inflection Point for Semis

1:41 to 4:59

Discussion on the current state of semiconductor stocks and market trends.

“Come to you live from Studio B at the NASDAQ.”

Impact of Rates and Inflation

4:59 to 6:44

Analyzing the effects of interest rates and inflation on the market.

“So I think I'm more in the SMH camp because if earnings, they're going to be the net recipients of those CapEx dollars of 1.3 trillion.”

Healthcare Sector Performance

6:44 to 8:27

Exploring the performance of the healthcare sector amidst market changes.

“They keep using these phrases like, oh, it's going to go up substantially moving forward.”

Novo's Capital Markets Day Preview

8:27 to 11:20

Preview of Novo's upcoming event and its potential implications for the market.

“And as long as that still takes place, whether it's on a relative basis or not, it's still going to keep the market moving forward.”

Market Trends and Strategies

11:20 to 14:00

Discussion on broader market strategies and investment opportunities.

“Joining us for more is Mizuho Healthcare Specialist, Jared Holt.”

Pharmaceutical Market Dynamics

14:00 to 17:43

Discussion on the current performance and strategies of major pharmaceutical companies.

“I mean, And the stock reactions out of other competitors on good data has been very lackluster, I think, because we have all sort of determined that Lilly has won, at least for now.”

Apple's Product Launch Analysis

19:12 to 24:37

Insights into Apple's iPhone launch and the implications for market demand.

“This is Fast Money with Melissa Lee right here on CNBC.”

Evaluating Apple's Valuation and Market Strategy

24:37 to 28:01

Discussion on Apple's pricing strategy, margins, and global market positioning.

“And I think that's exactly what we need to see.”

State Dinner Attendance and U.S.-China Relations

28:06 to 29:19

Details about the upcoming state dinner and its implications for U.S.-China relations.

“CNBC's Megan Cassell has got the latest.”
Show all 24 chapters

Developments on Greenland Security Agreement

29:20 to 30:20

Discussion on the new security agreement between the U.S. and Denmark regarding Greenland.

“So that's the sort of thing we'll be watching for next week.”

Market Impact of Upcoming U.S.-China Meeting

30:21 to 31:27

Analysis of how the U.S.-China meeting may affect various market sectors.

“But at the same time, we are looking at sectors, ag, chips, as you mentioned, tech.”

AI Regulation and China's Approach

31:28 to 32:32

Discussion on AI regulation in China and the potential for lessons in the U.S.

“I just think trading around China tech is something that's not always based on fundamentals.”

Teaser for Upcoming Guest

32:33 to 32:45

Teaser about the next guest's investment strategy heading into Q4.

Market Recap and Focus on Tech Stocks

32:46 to 34:28

Recap of market performance focusing on tech stocks and Bitcoin.

“Welcome back to Fast Money Stocks, wrapping up a volatile week with the Dow down 1.7 % since Monday, its worst week since March.”

Navigating Market Uncertainties

34:29 to 38:25

Discussion about market uncertainties, interest rates, and investment strategies.

“And it's this quality and broadening diversification, not only within sectors or regional, but also within technology itself.”

Opportunities in Cash and Short-term Bonds

38:26 to 39:47

Exploring the benefits of cash and short-term bonds in the current market.

“I wouldn't say I like cash, but I love the fact that we can now invest in short-term bonds.”

Anthropic's IPO Delay and Market Reactions

39:48 to 41:00

Discussion on Anthropic's delayed IPO and implications for the AI industry.

“Anthropic was reportedly expected to make its debut in October.”

Nike's Market Challenges and Future Outlook

41:01 to 42:00

Analysis of Nike's challenges following a partnership shift by a star athlete.

“A French soccer star is kicking Nike to the sidelines and what it could mean for the stock long term.”

Nike's Challenges in a Fragmented Market

42:00 to 43:31

Discussion on Nike's current market position and challenges due to competition.

“And in Nike's case, the problem here is, to me, it's ubiquity.”

Disney's New CTO and Technology Strategy

43:31 to 44:58

Overview of Disney hiring a new CTO and the implications for its tech focus.

“Disney announcing it is hiring its very first chief technology officer, the latest move by new CEO Josh DiMaro, to expand its tech and AI footprint.”

Interactive Characters on Disney Plus

44:58 to 46:14

Discussion on the potential for interactive AI characters on Disney Plus.

“So, Julia, didn't Disney at one point have some sort of partnership and explored characters using AI and the ability to interact with them and then decided to back away?”

Expanding Disney's Business Model

46:14 to 47:00

Exploring how new technology can enhance Disney's revenue streams.

“But I do like, I mean, this is really additive to their flywheel business.”

Expanding Disney's Business Model

47:03 to 47:28

Exploring how new technology can enhance Disney's revenue streams.

“Never bet against American grit or American energy.”
Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00At Edward Jones, we believe rich isn't about having life all figured out. It's opening yourself to all the possibilities. That's why your dedicated financial advisor provides long-term planning built around you. Meeting you where you are and helping you get closer to where you want to be. So no matter where you're starting from, you can move forward with confidence. The key to being rich is knowing what counts. Let's find your rich. Edward Jones, member SIPC. Mazda has been named Consumer Reports' safest new car brand. It starts with our approach. Every Mazda comes standard with proactive safety features.

0:41So you're more aware of what's around you, more focused on the road ahead, and ready before problems ever start. Mazda. More of what matters most to you. Go to mazdausa.com to learn more. Consumer Reports does not endorse or promote any product. Live from the Nasdaq MarketSide in the heart of New York City's Times Square, this is Fast Money. Here's what's on tap tonight. Semis at a crossroads. The group trading well off record highs, but what happens next could set the tone for the trade and the markets. Which way is it going? The traders will weigh in. And healthy gains after what has been a very volatile week.

1:19Healthcare and biotech came out as winners. Is this a sign of a broader rotation? Are there more games to come? Plus, a look at the demand for Apple's newest non-fotable phone. Tim might want to listen to that one. Nike loses another star athlete and a milestone higher at Disney while the company is bringing on a chief technology officer and how it could impact the future for the entertainment giant. I'm Melissa Lee. Come to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Courtney Garcia, Steve Grasso, and Julie Beal. And we start off with that potential inflection point for semi-stocks.

1:50A group up more than 2 % today with outsized gains in names like Teradyne, KLA Tencore, and Monolithic Power. But looking back at the quarter, these stocks are far underperforming software, down double digits compared to a 15 percent gain for the IGV and Q3. And the chart master says what happens next could be key. Carter Braxton Wirth out with a note this morning noting converging trend lines in the chart. But will the stocks break to the upside or break down from here? I love it when he sends this out. It's like a wedge. And then the arrows go up and down. And then you've got to figure it out.

2:25And what's your vote? Well, I mean, Carter does a great job of breaking those things down. My sense is that semis are breaking higher. My sense is that they've endured an enormous amount of pressure. I think, you know, remember where we walked in this week, we had every AI leader out there over the weekend talking about maybe tapping the brakes a little bit. I think as we go into the Trump-Xi summit, it's really clear that the U.S. and China are going to find no common ground on cutting back on AI. I mean, this is kind of what it's about. It's a race for supremacy. Therefore, I don't think also on the legislative front, even though it's a midterm topic, it's not really a midterm reality.

3:02This is not going to be part of the midterm vote. I understand data centers is a popular topic. It all comes back to there's no letting up on this story. And I think there's no letting up on the CapEx and the 1.3 trillion that will be raised next year for CapEx for the hyperscalers. All that means more growth. I think they've traded remarkably well, given how negative the sentiment is. And I think you're starting to see sentiment pick up in some other Momo names. The only thing I would hold out there or I would just say this is subject to what's going on in rates markets and oil markets. And, you know, a big part of today was just what we were hearing, what's going on in the oil prices, markets, North Sea premiums at record highs for refiners.

3:41I mean, this is getting worse, not better. And this is something that also is forcing all risks to come back in. At the same time, Brent coming below$100 a barrel, 10-year yield going below 5 % or staying at 5%. This sort of gives permission for some of these trades to keep working. Yeah, and I think the fact that these trades have actually been holding up pretty well, despite the fact that oils have been over$100 a barrel, the Fed is raising interest rates. There's a lot of reasons that markets should be selling off. And yes, they're off their highs, but really not as much as you would think on that news.

4:11So I actually do see that as a positive sign. And I think as we get here closer to October and we're going to refocus again on earnings season now that that's coming through, I think that's going to be a positive for the markets. And I do agree with you. I think demand is not the issue with the semi trade. Obviously, this this A.I. doomsday scenario that everybody's talking about right now is taking over the headlines. But I think when we get back to fundamentals and demand and CapEx, I think that conversation restarts. And I do think that's positive for that trade. So when you look at the when you look at SMH, when you look at the Sox, you break it down.

4:38So obviously, the Sox have outperformed on a year to date basis. And then you look at where are the estimates going? Is it higher for NVIDIA? Is it higher for Micron? So I look at it through those two prisms. Then when you look at the breakdown, SMH, 22 percent weight for NVIDIA, 5 percent weight for Micron. Now you do the reverse. Sox is 9 percent weight for NVIDIA and and and around a 9 percent weight for Micron. micron. So I think I'm more in the SMH camp because if earnings, they're going to be the net recipients of those CapEx dollars of 1.3 trillion. That's moving up. They're going to be the net recipient of it.

5:15The weight is going to be on memory. So memory is going to crash Apple and NVIDIA's margins, but the still net recipient of that money is still going to be NVIDIA. NVIDIA carries a bigger weight and they've definitely lagged. So I'd go with SMH for 300 jack. Okay. So if the CapEx story remains intact, the AI story is intact, Julie Beal, then do we not like hyperscalers anymore because they have to spend lots and lots of money still that the pressure is not off of them? Yeah, I think that's still the very big challenge, you know, because as there's been more and more reporting on the makeup of their AI revenue, the AI revenue growth has been certainly very impressive.

5:55But the problem is, is that you You have massive, massive customer concentration with Anthropic and OpenAI. And to the extent that people are concerned about their ability to do that business profitably, it calls into question, what is the strength and how much am I willing to pay for this AI revenue with the hyperscalers? So I think it's still actually a pretty tricky proposition because it's very opaque. But what I do think is that at least for the next quarter or two, the semiconductors are still very well positioned. Or did we hear enough from some of the hyperscalers like Ometta about monetization?

6:29And so the narrative has shifted a little bit. I mean, it has thus far. Those who can show the monetization story or at least the path there to it, those have been benefiting much better than those who can't. But I do think here, again, as we get into this new earnings season, that is going to be the key factor is not only what does last quarter look like, but that earnings go, I'm sorry, the capex going forward. They keep using these phrases like, oh, it's going to go up substantially moving forward. I think seeing what that goes up to, like at some point, the markets are going to get concerned about that.

6:57Yeah, I think we're getting a little bit of information on ROI. And I think it's not awful. I don't think they're going to stop spending. I do think it changes the multiple we think about them. I do think the story for mega cap tech, which over the last couple of weeks has been well supported in a world where maybe they'll spend a little bit less. I still think that the biggest stocks in the world. And again, that chart in the triple Q's or the NASDAQ 100 looks to me a lot like the semis chart. And I think one equals the other. And as we just, you know, Steve talked about some of the mechanics and the numbers and the weightings.

7:26But I mean, ultimately, the triple Q's go as also not only mega cap tech, but also semis go. So I think it's a it's a case where the entire market. And I said this yesterday. I mean, if we weren't in the month of September, I think it'd be really easy to say. And, you know, you shouldn't be trading on the calendar. I'm just saying there are dynamics out there with oil and and certainly what's going on with the inflation front. And, you know, we're waiting a couple of weeks now for earnings, which typically have been that reason to give markets the next piece of information to take the bottom up trade higher from the top down.

7:58Everyone always loves the seasonality. I love the seasonality of the calendar. But the major event was the Fed. And once you get that behind you where the markets look at it and say, OK, in the greater scheme of things is 25 basis points, a quarter point really going to let me pull or make me pull money out of the market. The answer is no. Are earnings still there? Are they still rising? And it's still in a handful of names, right? So we still have a handful of names that are doing the heavy lifting for the indices. And as long as that still takes place, whether it's on a relative basis or not, it's still going to keep the market moving forward.

8:34And I'll add one last thing. The majority is passive investing. People are putting money into this market, whether they know it or whether they don't. It's coming into this market. All right. We had a headline earlier this week, and we didn't really discuss it because of the Fed. It happened the same day. But Nebius, the neocloud raising prices by about 20 percent or so on compute. Does this how do you think, Tim, how do you think about this headline and this price increase and what it means to semis? Because it does prove that older semis still have worth for longer, which is a good thing, but maybe not necessarily a good thing for the semiconductor manufacturers.

9:10manufacturers. Right. Well, it's old as new, et cetera. I do think it's a case that shows that there's no choice, but both there's pricing power. And I think there's no choice but to continue to play the game. I think the whole the whole kind of stakes are getting ratcheted up for everybody. And it's we even talked about it as it means for Best Buy, because higher memory prices ultimately mean higher prices paid by consumers. And that's actually a good thing. So I think it's supporting everything we just said. And I think it's a it's a it's a valid point. I think there are a lot of stories below the surface that have been taking place, which are showing that legacy players and those folks with pricing power are exacting that upon their customers, and customers can't do anything but say, I'll take some more.

9:50Well, healthcare bright spot this week, the best performing S &B sector up almost 2 % since Monday. Biotech and device makers were the subgroups leading the charge. Revity, Moderna, Dexcom, Thermo Fisher among the biggest percentage gainers. This is interesting because there's conventional wisdom out there. Higher rates are not good for biotechs. That obviously was not the case. Yeah. And I think this is also a case where people are starting to look outside of the AI trade. I mean, I think people are starting to look for other areas of opportunity. This year has been a really good example of that.

10:20And I think healthcare does remain a place that is good to be invested in. And you're seeing a lot of these healthcare names that are also mentioning how AI is benefiting them just in their day-to-day businesses. They're not having to spend these huge CapEx numbers, but it's making them more efficient. It's making their pipelines shorter timeframes moving forward. And I think you're going to see that story continue. So I think this is absolutely something you want to be invested in. Yeah. Julie, where do you find value in health care? Yeah, I agree. I think that there is a lot of opportunity in these biotech names.

10:47The problem is that they just really do have a lottery ticket approach to them. So you're probably better served with an ETF. And me, I really love these niche health care companies like a LaMetra or even a hinge where they're really using AI to their benefit. And I think it's made them a much stronger business as a result. All right. Well, one potential catalyst for pharma next week is Novo's Capital Markets Day taking place on Monday. The Ozempic Maker is set to give more detail on the rebrand announced this week to Novo. And its accompanying business culture shift. Shares still down 15 % so far this year.

11:20Joining us for more is Mizuho Healthcare Specialist, Jared Holt. Jared, great to have you with us. There's so much to unpack on Novo. I first want to ask you about health care, because in your note, you actually acknowledge that conventional wisdom about rates and biotech and how the numbers actually history proves it wrong. It's not necessarily bad. Yeah, that's what I've gotten. If you go back to 2006, I'll call it 20 years, and you look at interest rates versus biotech, there really isn't that strong of a correlation. I think we all think there is because the pandemic was so vital in terms of you got a huge move in biotech to the upside, rates were zero.

11:56We're never going to see that again. And that, to me, was such a one-timer. If you back that out of the chart, there's really no correlation. Again, I think investors are, it's almost self-fulfilling. Everyone thinks it. And so I think biotech has been a little bit enigmatic as a place to invest over the past month or so. But when you look at the data, it really doesn't show a strong link at all. All right. Let's fast forward to Novo. What are we expecting, if anything, from this Investor Day meeting? I don't know, actually. I think I think part of it is just rearticulating the fact that there is a pipeline here beyond Wegovi.

12:30I mean, that part of that is going to be Cagre-Sema and other drugs that we've talked about that I think I don't think the street is too excited about, quite frankly. I think the other side of it, obviously, is business development. How does the company are they going to announce something? That's unclear, but are they going to point towards some of the assets that they might look to be interested in, at least from a therapeutic segment point of view? I would expect some of that. They've been very forthcoming lately in terms of the fact that they think they need to do more deals inside of obesity and outside.

12:58That could literally be anything. I think the street is so focused on what they don't have versus rather than what they do, because they've, for all intents and purposes, lost the obesity race to Lilly already. If they are going to make an acquisition, which is widely expected at some point in time, would you want them to be in the metabolic space or the obesity space or elsewhere? At this point, probably elsewhere, unless they found a modality that was so compelling, like a less frequent version of what they had or better efficacy. I'm not really sure that any of that is on the table over the near term, at least.

13:34I mean, we talked about Amgen and there are a bunch of other companies that have less frequent duration products that are in phase two or phase three. I'm not really sure how close Novo is to that. I mean, they tried to acquire Metzera. They were outbid by Pfizer. That actually turned out to be a good outcome for them. I'm not sure. I think I'd rather see them go outside. I mean, the Wegovi pill has actually been amazing and no one cares. I just feel like the street is moving past obesity, at least for them and for a lot of other players on the street. I mean, And the stock reactions out of other competitors on good data has been very lackluster, I think, because we have all sort of determined that Lilly has won, at least for now.

14:14So that's where I wanted to go. So if you look at Lilly, Lilly's up about 7 % year-to-date. Nova's down 15 % year-to-date. What's up 40 % year-to-date? Merck, are we all looking in the wrong direction because it became a two-horse race, but those two horses are not providing the year-to-date performance? Would you go in a totally different direction? Yeah, the market, again, this year, the market has essentially decided that obesity wasn't it. That was a theme of last year and the prior year as far as generating positive P &L. Merck has re-rated completely on business development decisions, in my opinion.

14:50It's gotten the focus away from this Keytruda concentration. They've done five deals over the past year or so. Investors have walked away thinking that was a really pragmatic approach to changing the strategy. You really haven't seen that with Lilly and Nova. I mean, to Lilly's credit, they've done a lot of smaller deals. They just have not seen the benefit on revenue yet. And Novo just has made so many missteps. A lot of pharma companies have outperformed those two. Again, I think this market is the best one in terms of revenue, but we haven't really seen anything drastically change for either of these companies from a top-line standpoint this year.

15:22So, Jared, does this also mean that they're kind of the race for GLP from everybody else other than those two, that things are cooled? I mean, we've had numerous players, whether it was Pfizer or folks that thought that they were actually entering in the race. And at times that was a small pop or a mildly sustainable pop. Does this say something more overall about GLP? Because, again, whether it's the oral pill, whether it's price headwinds that we've priced in there, we see there's an international market for Novo, whether it's Germany's opening up. It still doesn't mean anything. Does this tell me that GLP as a trade is done?

15:58I think for the time being it is, we're going to have to see what happens. The big transition, I think, that took place this year is not that GOPs became a bad idea as an investment for companies. I just think they became more consumer oriented than therapeutic. And the data that we've had from Lilly and Novo have actually been so good. It's tough to sort of supplant that in any way for other pharma companies. They're going to have to figure out a way to either be there. No one's going to be close. No one's going to be close in terms of timing, right? There's now a three or four year delay for the next best pharma company.

16:35So you have to bring something better. I just don't think we've seen that. The other thing is, like you mentioned, the pricing dynamic. We've talked about this before. It's basically the one thing that couldn't happen, which was pricing degradation to this extent. When we first started talking about this, the drugs were$1 ,200 a month and now they're$300 or$400. So that's been a big thing, too. But they're selling more, to be fair. In terms of it becoming a consumer product, why is that necessarily a negative at this point? Are you implying that people roll off of it quicker? Because it seems like they may roll off, but the weekly script numbers are still pretty decent.

17:10And so people would be going back on. So what makes the difference if it's a consumer product or not? It's not necessarily bad. I think that, like you mentioned, the volumes have been off the charts. But the pricing, when it's a consumer-driven market and you're dealing with so much out-of-pocket pay like you are here, I think it becomes a little bit of an issue for a time. I do think we're going to get back when we get incremental data sets out of these companies and other competitors. I think GLP-1s will come back. I think this was the year where we sort of, like, transitioned out of them temporarily.

17:41We'll come back to them. All right. Jared, great to see you. Thank you. Thank you. Jared Holtz of Mizuho. Which pharmaceutical do you like the best? You know, I know we always play would you rather here, but I do think in this environment, I think this was laid out really well. We're not just talking about GLP ones. It's what's next after that. And I do think that Lilly's pipeline is much better than Novo's. But I also think Steve brings up Merck here, which I think has really gotten past their key true to Patent Cliff, which people are really worried about. I would take actually them over the other two.

18:11You know, back to the Novo investor day, I think they have a lot to prove, but I think they're going to reiterate the same things. It will be interesting to hear what we hear about the almost the lateral pipeline, metabolic and and and the things that you almost feel like they have something up their sleeve. But in the short run, I think it's all about pricing. Where does pricing go in the U.S. and how much lower can it go? Yeah. So with Merck, everyone, we all look out on Keytruda, potentially losing 80 percent of their revenues. And this is the stock that outperformed everybody. But when you look on a technical basis, another stock that's interesting is AbbVie.

18:48And just cleanly on a technical basis, the stock looks like it wants a break hire. Coming up, another test for Ternus. The new iPhone 18 Pro going on sale today. Our customers upgrading to the latest devices. And what could it mean when the foldable launches next month? Plus, joining the party, what to expect from next week's meeting between President Trump and China's Xi Jinping. Don't go anywhere. Fast Money is back in tune. This is Fast Money with Melissa Lee right here on CNBC.

19:25Did you know that Neurosymbolic AI can help your business find new ways to make money? EY Parthenon is the only one offering this groundbreaking growth platform. Neurosymbolic AI analyzes hundreds of millions of data points to reveal new growth strategies. EY Parthenon teams deploy this innovation so you can uncover hidden value and scale beyond existing boundaries. Want to know what neurosymbolic AI can do for your business? Contact EY Parthenon today. Solutions that work in practice, not just on paper. Never bet against American grit or American energy. Through innovation, Venture Global is not only building some of the largest energy facilities in the world right here in the United States, but delivering American energy at a fraction of the cost and a fraction of the time.

20:14So while others are busy talking, we're busy building. That's Venture Global. That's unstoppable energy.

20:26There is so much NFL on ESPN right now. Monday Night Football, plus pregame and postgame. NFL Live, NFL Primetime. Everything you need to stay on top of every game, every week. Unbelievable. And now NFL Network is on the ESPN app. More football, more coverage, more ways to watch. Football's on, all season long, on ESPN and streaming on the ESPN app. Welcome back to Fast Money. Apple's iPhone 18 Pro and Pro Max are now officially on sale, marking the first product launch of CEO John Ternus' still short tenure. For a look at how demand stacked up to previous launches and what it means for the tech giant, let's bring in Mackenzie Cigales.

21:11Hey, Mac. Hey, Mel. Even with shares lower today, Apple's still up 24 % this year, more than double the S &P's gain and the best-performing MAG7 name. So the question is what has to go right from here? And on the hardware side, Apple's facing very tough comps after the 17 super cycle. And while early lead times for the new ProPhones are a little shorter than last year, Morgan Stanley says that doesn't necessarily mean weaker demand. Apple is nearly 20 % more Pro and Pro Max supply this time around, so greater inventory can naturally mean shorter waits. The demand picture also harder to read because Apple is splitting the iPhone cycle into three distinct releases.

21:49You've got the Pros now, the foldable Duo next month, and then lower-priced phones expected in the spring. Plus, some buyers may simply wait to compare the Pro Max with the Duo before deciding. Now, the street says the better barometer actually comes two weeks from now when lead times typically peak. And we'll see whether they keep stretching or start coming back in. And then there's valuation. Apple's trading around 35 times forward earnings near the high end of its historical range. For the stock to keep working from here, investors are going to want to see earnings estimates move higher. Mel?

22:21Yep, certainly will. Mac, thanks. Mackenzie Cigalos. Julie Beal, is Mac worth the price? Mac. Apple. It's a big multiple. It's a really, really big multiple. And I think that the challenge that we have is it's unusual to have these phone cycles where they're spread out so far apart. I do think that it sounds like there's a lot of interest and people feel like it's an incremental buyer that's a little bit different for the duo. But I do think that there's a real challenge for them to drive this much growth on top. So for me at this price, it's uncomfortably expensive. Tim's going to buy a phone soon.

Read the full transcript

22:57Yeah, I mean, at least one. No, probably just probably just one and and probably not waiting for the foldable. And probably, you know, as much as that's going to be cool, I think it's probably time to head to the store this weekend. I think the more interesting thing really on this release is China and other parts of Asia. So China's not I think they're 25 days out, 26 days out. Japan is probably, you know, 15 to 20 out. I want to see where demand really is in the markets. Certainly China, which could be a lot more price sensitive and has a very different competitive landscape. The valuation in Apple hasn't really mattered for a long time.

23:33I think it's given the benefit here of both being defensive at a time when also balance sheet does matter. And at a time, this is the first time in a long time there's really a growth story here. I think the lead time, you know, the Wall Street community likes to kind of geek out on lead times and what that means for real demand. As we've just heard, this time is out the window. So I'm pretty excited. When you look at the stock price, stock price is probably 2 % off all time highs basically around here. and everyone was worried about the cost of the phone. But the cost of the phone has been eaten up by the subsidies by the carriers.

24:03So they're taking some of that hit. And then you get your trade in. And then everyone does this on a zero interest monthly payment anyway. And the last reason why I think it's a buy still here is that we have services, 75 % margin on that business, and it's 42 % of the business and growing. I think it's still a buy. Well, I mean, the margins, though, on these phones are in question. We'll see about them when they report earnings. But there is a question regarding memory prices, but also for the duo, whether that margin will actually be higher, higher selling price, but at the same time, more materials that go into that phone, which could eat at margins.

24:37Correct. And I think that's exactly what we need to see. But I think that the idea is that if they can pass at least some of this on to consumers, and I think the idea is, at least based on what we're seeing today, that is hopeful that that's going to happen. It shouldn't weigh as much on their margins as I think people were fearing. But I do think they're doing a lot of things right here. Like people were really questioning their AI story for so long. We're now seeing that they want to have compute on device, and they're starting to make this a lot more safe in this environment, is their speak.

25:00But I like that they're spreading out the iPhone cycle. This isn't going to be so chunky now in one quarter. You're going to be seeing this get spread out. But I do agree. My biggest concern with Apple is nothing they're doing strategically. It's just the multiple on there. And I think it's just getting priced to perfection. So we own it. We will still own it. But I wouldn't be adding a ton more at these levels. I think you just want to continue to hold it. I mean, Apple here is more. And granted, it has had a premium multiple. but it is more expensive than almost every AI stock that we talk about.

25:28Look, it's multiple relative to itself has gotten kind of silly. I just, I don't know, I kind of feel like when we talk about margins and we talk about what's going on with memory prices, I also think at some point that's going to be a tailwind. I realize we have to look out, you know, maybe two or three years, but at some point memory prices will come down and Apple's proving that they have pricing power and this is where they'll actually maybe even be in margin story, but you're right, it's expensive. There's a lot more Fast Money to come. Here's what's coming up next. A seat at the table. All the industry leaders joining next week's state dinner with the Chinese president and how AI could take center stage at the summit.

26:06Plus, navigating an expensive market, one money manager's playbook for investing amid the recent volatility and the areas of the market where she's putting cash to work. You're watching Fast Money live from the NASDAQ market side in Times Square. We're back right after this.

26:29Never bet against American grit or American energy. Through innovation, Venture Global is not only building some of the largest energy facilities in the world right here in the United States, but delivering American energy at a fraction of the cost and a fraction of the time. So while others are busy talking, we're busy building. That's Venture Global. That's unstoppable energy.

26:58There is so much NFL on ESPN right now. Monday Night Football, plus pregame and postgame. NFL Live, NFL Primetime. Everything you need to stay on top of every game, every week. Unbelievable. And now NFL Network is on the ESPN app. More football, more coverage, more ways to watch. Football's on, all season long on ESPN and streaming on the ESPN app. When you partner with CDW, you get more from your devices with solutions that take modern work to the next level. CDW experts are delivering powerful productivity with Lenovo AI PCs. Helping users block out distractions, access virtual support anytime, anywhere, and share content seamlessly between devices.

27:52Make amazing happen. Learn more at cdw.com slash Lenovo.

28:00Welcome back to Fast Money. We are getting new details on who will attend next week's state dinner between President Trump and Chinese President Xi Jinping. CNBC's Megan Cassell has got the latest. Megan. Melissa, that's right. It is turning into quite the CEO-studded event next week. So far, CNBC has confirmed that NVIDIA's Jensen Huang, OpenAI's Sam Altman, Jamie Dimon of JPMorgan, and Citigroup's Jane Frazier are all expected to be in attendance at the dinner Thursday evening. Now, ultimately, we expect many other big-name tech CEOs to also confirm their attendance as well. Remember, Jensen Huang attended the state dinner that she hosted for President Trump in China back in May.

28:38Elon Musk and Tim Cook were there at the time as well. So we'll see who gets added to this list and whether any Chinese executives join the rakes as well. Now, the U.S.-China events around the state visit really kick off in earnest this weekend. That's when Treasury Secretary Scott Bessent will be leading meetings with his counterpart. I'm told those talks will focus on AI, trade, rare earths, and other economic issues, and that those working-level talks could continue into Monday. So that's where we expect any major deliverables to mostly be hammered out. That would be ahead of the leaders meeting.

29:09Based on my reporting so far, though, Melissa, expectations for major announcements from the summit are pretty muted. We could see things like an extension of the trade truce, possibly the establishment of an AI safety dialogue. So that's the sort of thing we'll be watching for next week. Melissa. All right, Megan, there's also been some developments on Greenland in just the past few minutes. What do you know there? Yeah, just in the last few minutes, It's the president posting on Truth Social about this. He says that the United States has entered into some sort of a new security agreement with Denmark over the security of Greenland.

29:41He says it will give the U.S. permanent control over security in Greenland and that it means no adversary can have a military presence there. He says this will also be at no cost to the United States. Just breaking here, so we will definitely need more details to find out what, if anything, will actually change in practice. We also need to hear from both Denmark and Greenland on this. I'll say, Melissa, for now, given that the president does say in this post that this arrangement will satisfy the concerns that he's had, it could at least mean the president will stop trying to annex or purchase Greenland or at least stop talking about it quite as much.

30:13Melissa. All right, Megan. Thank you. Megan Casella. It doesn't sound like anything at least considerable will come out of the summit. But at the same time, we are looking at sectors, ag, chips, as you mentioned, tech. I think the ag gets a benefit because China walks into this thing with the biggest trade surplus they've ever had. It's a bit ironic, right? This is what all we're talking about in terms of the trade front. And China's never had a bigger portion of global GDP at this point than they have now, but also on just the surplus front. I don't think they're going to get anything done on AI.

30:46And therefore, I think that underpins the argument in favor of the demand side. I do think there are stories that can be worked out. I think the thing I feel good about both geopolitically and otherwise is I think the diplomatic channels between the U.S. and China are as open as they've been in a long time. And I wouldn't say that about their core trading relationships. So I think it's I think it's generally bullish. I do think that there's dialogue there. I think China's always done what they've wanted to do with intellectual property. And that's not going to change. I would just quickly jump over to Alibaba, which is really underperformed in China tech today.

31:18Yeah. Yeah. I mean, in a nice little breakout. And the story around their cloud monetization and their AI growth and certainly their open source models is one that's, to me, so bullish relative to the stock performance that, you know, you have to scratch your head. I just think trading around China tech is something that's not always based on fundamentals. But some of this could be a trigger for China tech. Julie, what do you think of China tech here? Yeah, I agree. I think that the more I learn about how they're approaching AI, I think the more we could really learn from it. They have been really careful and thoughtful about their regulation in terms of what they allow as far as deep fakes and CSAM.

31:57They're really trying to be thoughtful about it in terms of using it as a tool that helps rather than gets rid of people. I think they've really demonstrated an ability that's thoughtful. So I think it'd be a great opportunity to learn. I don't think we will. But I think that, you know, any kind of discussion about what are possible safety approaches would be great. But, you know, I just don't think this administration is interested in that. Coming up, finding opportunity in the market swings where our next guest is putting money to work, heading into Q4 and her playbook for navigating the AI and tech trades.

32:29Don't go anywhere. More Fast Money in two. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

32:46Welcome back to Fast Money Stocks, wrapping up a volatile week with the Dow down 1.7 % since Monday, its worst week since March. The S &P 500 with a small gain today, but virtually unchanged for the week. NASDAQ and NASDAQ 100, though, logging gains, each posting their third positive week in four. And crypto cruising higher today. Bitcoin trading near$81 ,000 despite the recent failure of the Clarity Act in the Senate and the Fed's rate hike on Wednesday. What do you make of this run here? Yeah, so it's all about inflows and outflows. And in June, they had the biggest outflow in a while with about$3.5 billion coming out of the Bitcoin complex as far as ETFs are concerned.

33:22Then August reversed that. So you had$3.5 billion coming into it. And September's been actually positive. So Clarity is coming. It's just when does it actually officially happen? But the tailwind has been the inflows in the ETF market have been great net net for the year, though. Outflows still about one billion coming out of it. So I think you want to be hesitant around the eighty thousand dollar price target for Bitcoin right now. Wait till it proves itself to adding new money. All right. For what is next on the markets and rates. We are joined by Katerina Simonetti. She's executive vice president of Morgan Stanley, private wealth management.

33:59Katerina, great to have you with us. You think this market's expensive and potentially brutal and too concentrated, but you're constructive. What else is new? We love AI. We hate AI. We love data centers. We hate data centers. I think that the one constant that investors need to focus on is that this is our reality and we have to function in it. And within this uncertainty of the market and these high valuations, we need to find not only value, but also quality. And it's this quality and broadening diversification, not only within sectors or regional, but also within technology itself. It's what's going to get us through the volatility and allow us to truly take advantage of the opportunities in this very uncertain time that we live in.

34:53Which sectors do you think are most overvalued at this point? When we look at tech, it's not necessarily being overvalued, because of course it is. It is being enamored with these large 7-10 names, and it's the concentration risk. And in our view, what we tell investors, that this is not the time to chase these mega performers. This is the time to know what we own and being very, very selective, whether it's technology, whether it's financials, whether it's health care. It's owning companies that are positioned for durable growth and that also have the trend not only to show positive earnings, but also have positive earnings revision and have this competitive positioning.

35:37Katarina, so you're talking about asset allocation. You're definitely talking about diversification. And that's I'm sure your posture as an asset manager. You really don't want to lean too heavy into almost anything. And it doesn't mean you're you're you're copping out and you're hedging yourself. I mean, that is what what wealth managers do. And I think it's I think it's it's smart. What do you think technology should be as a as a waiting? I understand all clients have different risk profiles, but if the S &P is 40 percent tech when you add an Amazon and meta, just, you know, in I assume you want to be less than that.

36:08Can you give me some idea where wealth managers think about how much technology they want to have in a portfolio in today when we know it's already overweight, even if you just own the market? Well, it's a very fair question. And I think it's not as much about the weighting. It's about what we own, because we're going from the A.I. enablers to A.I. implementers. We're looking at this monetization story. So it is OK to own tech. And if it is OK for S &P 500 to be overweight in tech, it's certainly it's normal for investment portfolios to have a good representation or a larger, large representation in technology.

36:45It is about being diversified within technology and being very selective about the companies in terms of are we do we own software? Do we own semiconductors? Do we own AI users or the companies that are going to pave the way in how our health care companies and financial companies and industrials are going to use AI? That's the question is being diversified, not broadly as a general term, but being diversified within technology and within each sector. Now, one thing that's weighing on investors' minds this week is the Fed has raised interest rates. And I think at this point, they're digesting that pretty well.

37:19But now the concern is, do they keep hiking from here, right? Because can we handle one rate hike? Or are we looking at something like we saw in 2022, where you're seeing multiple rate hikes and equities don't like it as much? So what is your position here on where are rates going? Is this something you should be concerned about from an equity perspective? Are you changing any of your allocation based on that? It absolutely is a concern. While we don't see a repeat of 2022 where there's going to be this broadening hike cycle, this is definitely going to be data dependent. In our view, it's not the story of the rates.

37:50It's a story of the price of oil and inflation. And there are a number of factors that are going to go into the Fed decision, including the fact that they don't necessarily think that inflation is going down to that 2 % target rate that they have. And there is so much geopolitical risk. So assuming that the Strait of Hormuz situation gets resolved and we get some positive development and price of wealth starts coming down, maybe we're going to see the end of the hiking cycle way quicker than we think. But if it doesn't happen, it absolutely presents risk to equities. This is going to affect them in the negative way.

38:24One thing I do want to hit quickly is cash. You like cash. I mean, there's yield now. Yes. I wouldn't say I like cash, but I love the fact that we can now invest in short-term bonds. We can invest in three-month paper, six-month paper, you know, year in municipal bonds, in corporate bonds, and actually get some yield out of it. And this is a, you know, perfect story of making lemonade out of lemons, right? You know, on one side, of course, existing bond portfolios are going to, you know, feel the pressure of rising rates. But existing investors, people that are looking to place cash or diversify it out of equity risk, higher interest rate also present incredible opportunities.

39:04Katerina, great to see you. Thank you. Katerina Simonetti. How do you stand on CDs, short-term bonds, cash? You know, I actually think this is something investors want to be looking at because you bring up a good point where anybody who's in bonds right now hates them, right? Because what's happening is rates are going up, bonds are going down. Everyone's saying, why do we own these bonds right now? There's actually a really good time to be taking some profits off the table, off of your equities, which are doing really well, and be buying into some of these bonds, especially locking into some of these rates, which, you know, maybe we are assuming rates stay higher.

39:32And if that doesn't happen, you want to lock into these rates right now. So we're actually really looking at this opportunity, especially some of those high-tech states like New York and California. Munis are really attractive right now. We've got a news alert on Anthropic. The Wall Street Journal is reporting the company is shifting its planned IPO to November. Anthropic was reportedly expected to make its debut in October. The reported delay comes as the AI industry grapples with how to handle concerns about the speed of development. According to Kalshi, the probability of Anthropik announcing its IPO by November 1st has fallen to 6 percent.

40:05It will be interesting to see what the disclosures are in the S1, Julie, when your founder warns about the dangers to humanity and the economy, et cetera, of AI, of the very product you're making. I really have enjoyed all of the risk sections. the SpaceX risk section is absolutely worth taking a look at, because they're actually quite even-handed and honest about some of the risks to any of their forecasts. For sure, it's going to be a pretty central topic, but I think what everyone is the most interested in are going to be the unit economics. I think there's a lot of talk about the company's ability to be profitable on inference, and that's fine, but there's really no world, I think, in the near term where training isn't extremely expensive, so to not count it is weird.

40:53So I think looking forward, I'm dying to see this as swans. I'm disappointed that we have to wait a little longer. Coming up, a sneaker selection impacting two footwear giants in very different ways. A French soccer star is kicking Nike to the sidelines and what it could mean for the stock long term. That is next when Fast Money returns.

41:17Welcome back to Fast Money. Nike shares getting tripped up after a French soccer star player, Kylian Mbappe, pulled out of his long partnership with the shoemaker in favor of Swiss rival on-holding shares of Nike trading at more than 12 months. Excuse me. I gave it the benefit of the debt. No, 12 years lows. And on Monday, it will be kicked out of the S &P 100. Barron's also put out an article yesterday saying the stock's 13-year stay in the Dow could be in danger as well. Well, and yes, we know money is largely not indexed to the Dow at all. But just in terms of it representing great American companies, this really shows how far Nike has fallen.

41:54Yeah. And the time to buy Exxon was when it got kicked out of the Dow. But I mean, it's often indicative of really a point where things have, I don't want to say, bottomed out. And in Nike's case, the problem here is, to me, it's ubiquity. And where are the brands right now? I still want to say and I believe that Nike is the most influential athletic brand in the world. And I think they have a substantial lead. Having said that, there's an element of what's going on with the Nike shoes, whether they're going into the famous footwear or, you know, what happened to Under Armour is kind of what it feels like is going on with Lulu and Nike here, because the competition in more exclusive brands or brands that actually aren't available in straight retail.

42:35I just think that right now Nike is not out of the woods and it's not cheap. But dropping out of the Dow almost makes me want to buy it. Yeah, I don't think dropping out of Dow has any threshold of pain for you where you should say, OK, it's dropping out of the Dow, so I have to exit it. As you said in the lead up, there's a lot less passive money in the Dow chasers than there is in the S &P. So it stays in the S &P. It's symbolic. Sentiment. And it's sentiment to just look at the chart. So the chart from 2021, it's in a declining trend line. It's got a host of reasons why it used to be king of the hill, and now it's having trouble being relevant anymore.

43:15So they're still massive. They're still the biggest out there. But the problem is the market's so fragmented, and there's probably three or four things they can do to turn around, none of which they've done. Coming up, Disney looking for some AI magic, the new hire they're making, and what it means for the changing media landscape. More fast money, too.

43:41Welcome back to Fast Money. Disney announcing it is hiring its very first chief technology officer, the latest move by new CEO Josh DiMaro, to expand its tech and AI footprint. Julia Borson is here with more information on this story. Hey, Julia. Well, Melissa, Disney is creating a new role of chief technology officer, which will report directly to CEO Josh DiMaro and is hiring for this new position, Karam Deep Anand. Until now, he's been the CEO of Character AI, which is a platform for talking to fictional and custom bots, with some of his team joining with him as well. Now, he was formerly at Brex, Meta, and Microsoft.

44:17This move by Josh Amaro, who's been a CEO for six months now, speaks to the value he places on technology as a growth driver for Disney and also to the power he sees in AI in particular. Amaro is saying, And quote, Karen Deet brings a rare mix of experience across infrastructure, consumer technology and AI, saying as we further our three priorities, great storytelling as our North Star, technology in the service of creativity and operating as one Disney. Now, this all plays into DeMauro's plan that he's talked about to use technology to deepen Disney's direct relationships with fans with Disney Plus as what he calls the digital centerpiece.

44:58Melissa. So, Julia, didn't Disney at one point have some sort of partnership and explored characters using AI and the ability to interact with them and then decided to back away? Well, so it did have a very big deal with Sora, which was OpenAI's generative AI platform. Sora was going to be licensing Disney characters and enabling people to create content with them. Sora then shut down. And so what that means for Josh tomorrow is probably a good thing. It means he can create his own tech vision, his own AI plans from scratch. Now, given how much DeMauro has talked about really driving people to be engaged on the Disney Plus platform, now that they have the character AI folks, I can imagine that they'll have the ability to talk to Mickey Mouse or Elsa from Frozen or any number of their characters directly on Disney Plus in a controlled environment.

45:53So certainly seems to be a lot of opportunity there for DeMauro's vision. And I bet parents will pay extra for it, too. Julia, thank you. Julia Boorstin, you've got young kids, so it sounds like an interesting thing. Do you want to talk to Elsa? I know. My kids love going to Disneyland and meeting Lightning McQueen. If they could talk to him every day, yeah, I'm sure I would pay for that. Absolutely. But I do like, I mean, this is really additive to their flywheel business. That is what they do is they find these characters, they license them, and they figure all the different ways that they can get to, whether it's merchandise, whether it's streaming, you know, whatever it is, this is additive to that, which I think is great.

46:26Up next, Final Trades.

46:56and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer. Never bet against American grit or American energy. Through innovation, Venture Global is not only building some of the largest energy facilities in the world right here in the United States, but delivering American energy at a fraction of the cost and a fraction of the time. So while others are busy talking, We're busy building. That's venture global. That's unstoppable energy.

From the publisher

A potential inflection point for semi stocks, as the group underperforms the software space this quarter. The divergence in the tech trade, and how it could set up the chip trade in Q4. Plus, an iPhone sales test for Ternus, how AI could take center stage at next week’s Trump-Xi summit, and navigating an ‘expensive’ market; how one money manager is putting cash to work amid the volatility.

 Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 870 episodes
Semis At An Inflection Point… And Navigating An ‘Expensive’ Market 9/18/26CNBC's "Fast Money" · 43 min
Listen in VO